Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 22, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details specific transactions executed on September 22, 2006, involving the GlaxoSmithKline (US) Trust ("the GSK US Trust") acting on behalf of participants in the GlaxoSmithKline Share Value Plan:
- Sales: The GSK US Trust sold 2,557 Ordinary Share ADRs at a price of $53.95 per ADR.
- Transfers: The GSK US Trust transferred 5,216 Ordinary Share ADRs to participants in the Share Value Plan.
Three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the shares held within the GSK Trust in the same capacity as other employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total volume of ADRs sold (2,557) and transferred (5,216) on September 22, 2006.
- Confirm the transaction price of $53.95 per ADR for the shares sold.
- Note that the transactions were executed by Abacus Corporate Trustees Limited as trustee of the GSK US Trust.
- Understand that the directors mentioned are interested in the trust shares as beneficiaries alongside other employees, not necessarily through direct personal trading.